Oncologic and fertility outcome in patients with advanced stage ovarian immature teratomas

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports Pub Date : 2025-03-11 DOI:10.1016/j.gore.2025.101715

Marino Giuseppe , Negri Serena , Testa Filippo , Giuliani Daniela , De Ponti Elena , Bombelli Martina , Giorgia Pecis Cavagna , Lugotti Daniele , Jaconi Marta , Casiraghi Alessandra , Bianchi Tommaso , Grassi Tommaso , Bonazzi Maria Cristina , Fruscio Robert

{"title":"Oncologic and fertility outcome in patients with advanced stage ovarian immature teratomas","authors":"Marino Giuseppe , Negri Serena , Testa Filippo , Giuliani Daniela , De Ponti Elena , Bombelli Martina , Giorgia Pecis Cavagna , Lugotti Daniele , Jaconi Marta , Casiraghi Alessandra , Bianchi Tommaso , Grassi Tommaso , Bonazzi Maria Cristina , Fruscio Robert","doi":"10.1016/j.gore.2025.101715","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Immature teratomas represent rare malignant ovarian germ cell tumours, typically involving young women<em>.</em> The majority of germ cell tumors (60%–70%) are diagnosed at an early stage, showing an optimal prognosis. However, advanced stages represent about one third of these patients. We report the oncologic outcome of this population, investigating also fertility outcomes in patients who underwent fertility preservation.</div></div><div><h3>Methods</h3><div>Clinicopathological data were retrospectively collected and analysed from a cohort of 17 post-pubertal patients with advanced stage immature teratomas in a single centre between 1980 and 2024.</div></div><div><h3>Results</h3><div>Among 17 patients included in the study, 76.5 % (13/17) underwent fertility-sparing surgery (FSS) and 23.5 % (4/17) radical surgery. Adjuvant chemotherapy was administered in 82 % (14/17) of patients. After a median follow up of 237 months (range 68.0–289.0), 2 patients had persistent disease after receiving chemotherapy and 3 showed relapse. Of these, two had a second relapse. All patients are alive without evidence of disease at the last follow up. Also 46 % (6/13) of women treated with FSS reached pregnancy.</div></div><div><h3>Conclusions</h3><div>FSS appears to be safe and effective in the treatment of advanced stage immature teratoma. Despite surgical interventions and the administration of chemotherapy in the majority of patients, fertility outcome is satisfactory.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101715"},"PeriodicalIF":1.2000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352578925000402","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Immature teratomas represent rare malignant ovarian germ cell tumours, typically involving young women. The majority of germ cell tumors (60%–70%) are diagnosed at an early stage, showing an optimal prognosis. However, advanced stages represent about one third of these patients. We report the oncologic outcome of this population, investigating also fertility outcomes in patients who underwent fertility preservation.

Methods

Clinicopathological data were retrospectively collected and analysed from a cohort of 17 post-pubertal patients with advanced stage immature teratomas in a single centre between 1980 and 2024.

Results

Among 17 patients included in the study, 76.5 % (13/17) underwent fertility-sparing surgery (FSS) and 23.5 % (4/17) radical surgery. Adjuvant chemotherapy was administered in 82 % (14/17) of patients. After a median follow up of 237 months (range 68.0–289.0), 2 patients had persistent disease after receiving chemotherapy and 3 showed relapse. Of these, two had a second relapse. All patients are alive without evidence of disease at the last follow up. Also 46 % (6/13) of women treated with FSS reached pregnancy.

Conclusions

FSS appears to be safe and effective in the treatment of advanced stage immature teratoma. Despite surgical interventions and the administration of chemotherapy in the majority of patients, fertility outcome is satisfactory.

查看原文本刊更多论文

晚期卵巢未成熟畸胎瘤患者的肿瘤和生育结局

背景成熟畸胎瘤是一种罕见的恶性卵巢生殖细胞肿瘤，多见于年轻女性。大多数生殖细胞肿瘤（60%-70%）在早期被诊断出来，预后良好。然而，晚期患者约占这些患者的三分之一。我们报告了这一人群的肿瘤学结果，并调查了接受生育保留的患者的生育结果。方法回顾性收集1980 ~ 2024年同一中心17例青春期后晚期未成熟畸胎瘤患者的临床病理资料进行分析。结果纳入研究的17例患者中，76.5%（13/17）的患者接受了生育保留手术（FSS）， 23.5%（4/17）的患者接受了根治性手术。82%（14/17）的患者接受了辅助化疗。中位随访237个月（68.0 ~ 289.0），2例患者化疗后病情持续，3例复发。其中，两人再次复发。所有患者在最后随访时均存活，无疾病迹象。46%（6/13）接受FSS治疗的妇女成功怀孕。结论sfss治疗晚期未成熟畸胎瘤安全有效。尽管手术干预和化疗的管理在大多数患者，生育结果是令人满意的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic Oncology Reports OBSTETRICS & GYNECOLOGY-

CiteScore

2.00

自引率

0.00%

发文量

183

审稿时长

41 days

期刊介绍： Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.